Salvage Therapies including Retreatment with BCMA-directed Approaches Following BCMA CAR-T Relapses for Multiple Myeloma
Copyright © 2024 American Society of Hematology..
For patients with relapsed/refractory multiple myeloma (RRMM) with relapse following B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapies (CAR-T), optimal salvage treatment strategies remain unclear. BCMA-directed CAR-T and bispecific antibodies (BsAb) are now commercially available, and the outcomes for retreatment with BCMA-directed approaches are not well-studied. We performed a retrospective analysis of 68 patients with relapsed disease after BCMA-directed CAR-T to evaluate outcomes and responses to salvage therapies. With a median follow-up of 13.5 months, median overall survival from time of relapse until death was 18 months (95% confidence interval (CI): 13.2 months-not reached (NR)). 58 patients received subsequent myeloma-directed therapies, with a total of 265 lines-of-therapy (LOTs). The overall response rate for first-line salvage therapy was 41% (CI: 28-55%). Among all LOTs, high response rates were observed among those receiving another BCMA-directed CAR-T (89%), BCMA-directed BsAb (60%), CD38-directed combinations (80% when combined with BsAb; 50% when combined with immunomodulatory drugs and/or proteasome inhibitors), and alkylator-combinations (50% overall; 69% with high-dose alkylators). Thirty-four patients received at least one line of salvage BCMA-directed therapy; median PFS was 8.3 months (CI: 7.9 months-NR), 3.6 months (CI: 1.4 months-NR), and 1 month (CI: 0.9 months-NR) with median duration of response (DOR) of 8 months, 4.4 months, and 2.8 months for subsequent BCMA-directed CAR-T, BsAb, and belantamab mafadotin, respectively. Retreatment with BCMA-directed CAR-T and BsAb can be effective salvage options post-BCMA-directed CAR-T relapse; however, DORs appear limited and further studies with new combinations and alternative targets are warranted.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
Blood advances - (2024) vom: 01. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Reyes, Kevin Robert [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 01.03.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.1182/bloodadvances.2023012066 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM369189639 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM369189639 | ||
003 | DE-627 | ||
005 | 20240302232920.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240302s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1182/bloodadvances.2023012066 |2 doi | |
028 | 5 | 2 | |a pubmed24n1314.xml |
035 | |a (DE-627)NLM369189639 | ||
035 | |a (NLM)38429087 | ||
035 | |a (PII)bloodadvances.2023012066 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Reyes, Kevin Robert |e verfasserin |4 aut | |
245 | 1 | 0 | |a Salvage Therapies including Retreatment with BCMA-directed Approaches Following BCMA CAR-T Relapses for Multiple Myeloma |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 01.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a Copyright © 2024 American Society of Hematology. | ||
520 | |a For patients with relapsed/refractory multiple myeloma (RRMM) with relapse following B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapies (CAR-T), optimal salvage treatment strategies remain unclear. BCMA-directed CAR-T and bispecific antibodies (BsAb) are now commercially available, and the outcomes for retreatment with BCMA-directed approaches are not well-studied. We performed a retrospective analysis of 68 patients with relapsed disease after BCMA-directed CAR-T to evaluate outcomes and responses to salvage therapies. With a median follow-up of 13.5 months, median overall survival from time of relapse until death was 18 months (95% confidence interval (CI): 13.2 months-not reached (NR)). 58 patients received subsequent myeloma-directed therapies, with a total of 265 lines-of-therapy (LOTs). The overall response rate for first-line salvage therapy was 41% (CI: 28-55%). Among all LOTs, high response rates were observed among those receiving another BCMA-directed CAR-T (89%), BCMA-directed BsAb (60%), CD38-directed combinations (80% when combined with BsAb; 50% when combined with immunomodulatory drugs and/or proteasome inhibitors), and alkylator-combinations (50% overall; 69% with high-dose alkylators). Thirty-four patients received at least one line of salvage BCMA-directed therapy; median PFS was 8.3 months (CI: 7.9 months-NR), 3.6 months (CI: 1.4 months-NR), and 1 month (CI: 0.9 months-NR) with median duration of response (DOR) of 8 months, 4.4 months, and 2.8 months for subsequent BCMA-directed CAR-T, BsAb, and belantamab mafadotin, respectively. Retreatment with BCMA-directed CAR-T and BsAb can be effective salvage options post-BCMA-directed CAR-T relapse; however, DORs appear limited and further studies with new combinations and alternative targets are warranted | ||
650 | 4 | |a Journal Article | |
700 | 1 | |a Liu, Yen-Chun |e verfasserin |4 aut | |
700 | 1 | |a Huang, Chiung-Yu |e verfasserin |4 aut | |
700 | 1 | |a Banerjee, Rahul |e verfasserin |4 aut | |
700 | 1 | |a Martin, Thomas |e verfasserin |4 aut | |
700 | 1 | |a Wong, Sandy W |e verfasserin |4 aut | |
700 | 1 | |a Wolf, Jeffrey Lee |e verfasserin |4 aut | |
700 | 1 | |a Arora, Shagun |e verfasserin |4 aut | |
700 | 1 | |a Shah, Nina |e verfasserin |4 aut | |
700 | 1 | |a Chari, Ajai |e verfasserin |4 aut | |
700 | 1 | |a Chung, Alfred |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Blood advances |d 2016 |g (2024) vom: 01. März |w (DE-627)NLM268683263 |x 2473-9537 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:01 |g month:03 |
856 | 4 | 0 | |u http://dx.doi.org/10.1182/bloodadvances.2023012066 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 01 |c 03 |